JP2015504893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504893A5 JP2015504893A5 JP2014551703A JP2014551703A JP2015504893A5 JP 2015504893 A5 JP2015504893 A5 JP 2015504893A5 JP 2014551703 A JP2014551703 A JP 2014551703A JP 2014551703 A JP2014551703 A JP 2014551703A JP 2015504893 A5 JP2015504893 A5 JP 2015504893A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- group
- polypeptide
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000005647 linker group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 229940076376 protein agonist Drugs 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 0 CC(C)C(C1(*)N(*)C=*1)=C Chemical compound CC(C)C(C1(*)N(*)C=*1)=C 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584675P | 2012-01-09 | 2012-01-09 | |
| US61/584,675 | 2012-01-09 | ||
| PCT/IB2013/050131 WO2013105013A1 (en) | 2012-01-09 | 2013-01-07 | Mutant antibodies and conjugation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504893A JP2015504893A (ja) | 2015-02-16 |
| JP2015504893A5 true JP2015504893A5 (enExample) | 2016-02-25 |
| JP6413127B2 JP6413127B2 (ja) | 2018-10-31 |
Family
ID=47678955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551703A Active JP6413127B2 (ja) | 2012-01-09 | 2013-01-07 | 変異抗体およびそのコンジュゲーション |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20130323234A1 (enExample) |
| EP (2) | EP2802355B1 (enExample) |
| JP (1) | JP6413127B2 (enExample) |
| AR (1) | AR090410A1 (enExample) |
| CA (1) | CA2863216C (enExample) |
| ES (1) | ES2700398T3 (enExample) |
| TW (1) | TW201341401A (enExample) |
| WO (1) | WO2013105013A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013343111A1 (en) | 2012-11-07 | 2015-05-14 | Pfizer Inc. | Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates |
| US9260478B2 (en) * | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| EP4025255A1 (en) * | 2019-09-04 | 2022-07-13 | Bolt Biotherapeutics, Inc. | Immunoconjugate synthesis method |
| CN112307622B (zh) * | 2020-10-30 | 2024-05-17 | 中国兵器科学研究院 | 一种用于计算机生成兵力的自主规划系统及规划方法 |
| EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| IL312142A (en) * | 2021-11-01 | 2024-06-01 | Dyne Therapeutics Inc | Muscle targeting complexes for the treatment of dystrophinopathy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| WO2004073656A2 (en) * | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| CN1835975B (zh) * | 2003-08-13 | 2012-11-21 | 辉瑞产品公司 | 经修饰的人类igf-1r抗体 |
| AU2006204459B2 (en) * | 2005-01-05 | 2012-11-01 | F-Star Therapeutics Limited | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| JP5167473B2 (ja) | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| WO2008020827A2 (en) * | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
| DK1933871T3 (da) | 2005-09-07 | 2013-07-08 | Amgen Fremont Inc | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
| KR20120043028A (ko) * | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| SG181814A1 (en) * | 2009-12-23 | 2012-07-30 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
| EP2593142B8 (en) * | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| PT3327027T (pt) | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
-
2013
- 2013-01-07 TW TW102100422A patent/TW201341401A/zh unknown
- 2013-01-07 EP EP13703151.4A patent/EP2802355B1/en active Active
- 2013-01-07 JP JP2014551703A patent/JP6413127B2/ja active Active
- 2013-01-07 WO PCT/IB2013/050131 patent/WO2013105013A1/en not_active Ceased
- 2013-01-07 CA CA2863216A patent/CA2863216C/en active Active
- 2013-01-07 ES ES13703151T patent/ES2700398T3/es active Active
- 2013-01-07 EP EP18192573.6A patent/EP3447071A1/en active Pending
- 2013-01-07 AR ARP130100061A patent/AR090410A1/es unknown
- 2013-01-07 US US13/736,029 patent/US20130323234A1/en not_active Abandoned
-
2020
- 2020-06-09 US US16/896,930 patent/US11780935B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504893A5 (enExample) | ||
| US11766482B2 (en) | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use | |
| AU2024202618A1 (en) | Bicyclic peptide ligands specific for EphA2 | |
| JP6787795B2 (ja) | 抗Ａｘｌ抗体 | |
| RU2012157167A (ru) | Полифункциональные антительные конъюгаты | |
| EP4001307A1 (en) | Antibodies against il-1 beta | |
| WO2022031871A4 (en) | Compositions and methods related to il27 receptor binding | |
| JP2019511201A5 (enExample) | ||
| US12351642B2 (en) | TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers | |
| CN106414498A (zh) | TNF α的结合成员 | |
| JP2022553826A (ja) | 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物 | |
| CN112638946A (zh) | 抗il1rap抗体组合物 | |
| WO2019246288A1 (en) | Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries | |
| JP2010501164A5 (enExample) | ||
| Wu et al. | Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation | |
| JP2019506140A5 (enExample) | ||
| JP2025026839A5 (enExample) | ||
| US20240294638A1 (en) | Anti-nkg2a antibodies and compositions | |
| JP2015520172A5 (enExample) | ||
| WO2023219147A1 (ja) | Ｃｃｒ８検出用新規抗ｃｃｒ８抗体 | |
| CN106536567A (zh) | 新型多肽 | |
| JP2017522864A (ja) | 新規ポリペプチド | |
| WO2017149311A1 (en) | Evasins for use in therapy and diagnostics | |
| US11807688B2 (en) | Anti-AXL antibodies and compositions | |
| JP2003510672A (ja) | 分子疑似体を作製するためのコンピュータによる設計方法 |